Utility of Apremilast in the Treatment of Psoriasis

International Journal of Basic & Clinical Pharmacology
doi 10.18203/2319-2003.ijbcp20183013
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Medip Academy

Related search

Psoriasis-Arthritis – Apremilast: Kein Zusatznutzen Ableitbar

Aktuelle Rheumatologie
Rheumatology
2015English

Treatment Persistence in Psoriasis Patients Initiated on Apremilast, Oral Systemics, or Biologic Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Pss23 - Switch Patterns and Total Costs in Biologic-Naive Patients Initiating Apremilast or a Biologic for the Treatment of Psoriasis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Comparison of Persistence Between Adults With Psoriasis Initiating Apremilast or Biologics

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Treatment of Psoriasis in the Army

BMJ
1918English

Pss15 - Budget Impact Analysis of Apremilast in Patients With Moderate-To-Severe Plaque Psoriasis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Treatment of Psoriasis.

BMJ
1966English

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis

Rheumatology and Therapy
2014English

Immunosuppressants for the Treatment of Psoriasis

Journal of Nihon University Medical Association
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy